Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

BACKGROUND: Overactive bladder (OAB) is associated with high healthcare costs, which may be partially driven by drug treatment. There is little comparative data on antimuscarinic drugs with respect to resource use and costs. This study was conducted to address this gap and the growing need for natur...

Descripción completa

Detalles Bibliográficos
Autores principales: Sicras-Mainar, Antoni, Rejas, Javier, Navarro-Artieda, Ruth, Aguado-Jodar, Alba, Ruiz-Torrejón, Amador, Ibáñez-Nolla, Jordi, Kvasz, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015546/
https://www.ncbi.nlm.nih.gov/pubmed/24144225
http://dx.doi.org/10.1186/1471-2490-13-51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015546/
https://www.ncbi.nlm.nih.gov/pubmed/24144225
http://dx.doi.org/10.1186/1471-2490-13-51

Ejemplares similares